A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis

NCT03482011 ↗

Phase 3 Completed 530 enrolled Eli Lilly and Company

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of mirikizumab in participants with moderate to severe plaque psoriasis.

Timeline

Start: 2018-04-24
Primary completion: 2019-03-21
Completion: 2020-01-16

Outcome

Met primary endpoint

registry analysis (superiority test); Placebo Q4W vs 250 mg Miri Q4W; p <0.001; Risk Difference (RD) 63.0 (95% CI 56.5 to 69.4); Cochran-Mantel-Haenszel NCT03482011 ↗

registry analysis (superiority test); Placebo Q4W vs 250 mg Miri Q4W; p <0.001; Risk Difference (RD) 57.8 (95% CI 51.3 to 64.4); Cochran-Mantel-Haenszel NCT03482011 ↗

Publications

Hsieh CY, Hsu FL, Tsai TF. Comparison of Drug-Free Remission after the End of Phase III Trials of Three Different Anti-IL-23 Inhibitors in Psoriasis. Dermatol Ther (Heidelb). 2024 Sep;14(9):2607-2620. doi: 10.1007/s13555-024-01229-6. Epub 2024 Jul 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mirikizumab	Monoclonal antibody	125 mg	Subcutaneous
Subject	Mirikizumab	Monoclonal antibody	250 mg	Subcutaneous